Belgrade 2018 Meeting Highlights Registration Abstract Submission Exhibition Virtual Exhibition Hotel Information Satellite Programme Visa Letter Application

Outcomes of corneal tattooing by Rotring painting ink in disfiguring corneal opacities

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Cornea
Session Date/Time: Friday 09/02/2018 | 08:30-10:00
Paper Time: 09:39
Venue: Annex A

First Author: A.Alsmman EGYPT
Co Author(s):                  

Abstract Details

Purpose:

Aim: To evaluate corneal tattooing with Rotring painting ink (Rotring Ink, Hamburg, Germany) as an available and affordable surgical technique to improve cosmetic appearance in eyes with disfiguring corneal opacities.

Setting:

Sohag Ophthalmology department,Sohag University Sohag Egypt

Methods:

Methods: Fifty three blind eyes with corneal disfiguring opacities underwent corneal tattooing using Rotring painting ink (Rotring Ink, Hamburg, Germany) was used by multiple transepithelial intrastromal injections under topical anesthesia. Complete ophthalmic examination, Ocular ultrasonography and photographs of the patients' eyes were taken. Follow-up period was at least 12 months.

Results:

Results: First day postoperative all patients presented by mild conjunctival injection and foreign body sensation. After the end of follow up period 48 patients (96%) were satisfied of cosmetic appearance while only 2 patients (4%) postop cosmetic results were less than their expectations however they were better in appearance. No major complications like corneal erosions; corneal ulcers or corneal melting was noted in any case.

Conclusions:

Conclusions: Corneal tattooing with Rotring painting ink in blind disfigured eyes achieves favorable cosmetic results and is associated with high patient satisfaction. With better case selection, a high postop satisfaction was achieved Corneal tattooing acts as an alternative to more sophisticated and expensive cosmetic reconstructive surgery.

Financial Disclosure:

None

Back to previous